Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Jan. 27, 2025

Abstract The newly emerged variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) demonstrate resistance to present therapeutic antibodies as well the capability evade vaccination-elicited antibodies. JN.1 sublineages were demonstrated one most immune-evasive variants, showing higher neutralization compared XBB.1.5. In this study, serum samples collected from adult participants including those who had gone through BA.5/BF.7, EG.5/HK.3 and XBB/JN.1 infection waves, characterized by different vaccination histories. We evaluated in these against pseudoviruses Omicron lineages. further investigated humoral immune response recombinant XBB vaccines estimated sublineages, KP.2 KP.3. Our results showed that sera previous circulating subvariant breakthrough infections exhibited low GMTs 50% all tested significantly elevated individuals received WSK-V102C or WSK-V102D boosters. Importantly, 4 months after a booster XBB.1.5, JN.1, JN.1.13, KP.3 3479, 1684, 1397, 1247 1298, with 9.86-, 9.79-, 8.73-, 8.66- 8.16-fold increase without booster, respectively, indicating boosting XBB.1.5 subunit still induced strong antibody responses sublineages. However, KP.3, revealed more than 2-fold decreases neutralizing titers suggesting enhanced evasion necessity boosters based on

Language: Английский

Tracking KP.2 SARS-CoV-2 Variant in India and the Clinical Profile of KP.2 Cases in Maharashtra, India

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 3, 2024

Background: Following the emergence of JN.1 SARS-CoV-2 variant, variants with key mutations in spike protein, such as L455F, F456L, and R346T, were identified. In early January 2024, KP.2 (JN.1.11.1.2) variant was first identified clinical samples. Its increasing global prevalence has raised concerns over its transmission impact. The study investigates KP.2*'s (*indicates all sub-lineages) spread severity Maharashtra. Methods: This involved 5,173 Indian whole genome sequences collection dates between November 1, 2023 June 24, 2024. Lineage analysis performed using Nextclade software (version 3.8.0). Telephonic interviews conducted to confirm demographic details obtain information on KP.2* cases. obtained data recorded analyzed Microsoft® Excel (Microsoft Corporation, Redmond, WA). Results: Among analyzed, JN.1* appeared predominant lineage (65.96%, 3412/5173), followed by (7.83%, 405/5173) KP.1* (3.27%, 169/5173). India, detected December 2, 2023, Odisha. majority from Maharashtra (248/405, 61.23%), West Bengal (38/405, 9.38%), Gujarat (27/405, 6.67%), Rajasthan (24/405, 5.93%). reported included 160 cases Of these, 95.63% (153/160) presented mild symptoms, fever (108/160, 67.50%), cold (87/160, 54.38%), cough (80/160, 50%), sore throat (44/160, 27.5%), body ache (43/160, 26.88%), fatigue (42/160, 26.25%). About 33.13% (53/160) required institutional quarantine or hospitalization, rest managed at home. those hospitalized, 50.94% (27/53) received conservative treatment, while 49.06% (26/53) needed supplemental oxygen, steroids, antiviral therapy. Regarding vaccination status, 89.38% (143/160) had least one dose COVID-19 vaccine, whereas 10% (16/160) unvaccinated, unvaccinated being children aged zero nine years (7/16, 43.75%). overall recovery rate for 99.38% (159/160), only 0.62% (1/160) succumbing disease. Conclusion: become dominant India Despite affected individuals experiencing studies have shown lower neutralization titers high infectivity due FLiRT mutations, suggesting KP.2's potential rise dominance.

Language: Английский

COVID-19 Surge During Summer 2024: The Phantom Menace?

Clinical Microbiology and Infection, Journal Year: 2024, Volume and Issue: 30(12), P. 1492 - 1493

Published: July 11, 2024

Language: Английский